You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

CLINICAL TRIALS PROFILE FOR TIKOSYN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TIKOSYN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00392106 ↗ High Intensity Focused Ultrasound (HIFU) Ablation System Study Suspended ProRhythm, Inc. Phase 3 2006-04-01 The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.
NCT00589303 ↗ AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study Terminated Medtronic Phase 3 2007-12-01 The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT00589303 ↗ AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study Terminated Mayo Clinic Phase 3 2007-12-01 The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).
NCT02308748 ↗ Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed Spaulding Clinical Research LLC Phase 1 2014-05-01 The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TIKOSYN

Condition Name

Condition Name for TIKOSYN
Intervention Trials
Atrial Fibrillation 2
Drug Toxicity 1
Drug-induced QT Prolongation 1
Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TIKOSYN
Intervention Trials
Long QT Syndrome 2
Atrial Fibrillation 2
Drug-Related Side Effects and Adverse Reactions 1
Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TIKOSYN

Trials by Country

Trials by Country for TIKOSYN
Location Trials
United States 23
Canada 1
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TIKOSYN
Location Trials
Minnesota 2
Ohio 2
Massachusetts 2
Georgia 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TIKOSYN

Clinical Trial Phase

Clinical Trial Phase for TIKOSYN
Clinical Trial Phase Trials
Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TIKOSYN
Clinical Trial Phase Trials
Terminated 1
Completed 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TIKOSYN

Sponsor Name

Sponsor Name for TIKOSYN
Sponsor Trials
Mayo Clinic 2
Food and Drug Administration (FDA) 1
Beth Israel Deaconess Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TIKOSYN
Sponsor Trials
Other 8
U.S. Fed 2
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.